What does this research mean for the field?

Annual PSA screening in BRCA2 pathogenic germline variant carriers detects clinically relevant prostate cancer at a higher incidence compared to noncarriers, and PSA screening in BRCA1 carriers leads to early detection of NCCN intermediate-risk and high-risk prostate cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To assess the effectiveness of annual PSA screening in detecting clinically relevant prostate cancer in BRCA1 and BRCA2 pathogenic variant carriers.

February 22, 2026European UrologyOpen Access

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

View Full Paper

Ask AI

Bookmark

To assess the effectiveness of annual PSA screening in detecting clinically relevant prostate cancer in BRCA1 and BRCA2 pathogenic variant carriers.
Conducted annual PSA screening for BRCA1 and BRCA2 PGV carriers.
Compared findings to noncarriers to evaluate differences in detection rates.
Analyzed incidence of clinically significant prostate cancer (csPC) and NCCN risk categories.
BRCA2 PGV carriers showed a higher incidence of csPC compared to noncarriers.
PSA screening in BRCA1 PGV carriers also detected early NCCN intermediate/high-risk prostate cancer.
Findings support systematic PSA screening for BRCA2 PGV carriers and suggested consideration for BRCA1 PGV carriers.

Implication

Annual PSA screening identifies clinically relevant prostate tumors in BRCA1 and BRCA2 carriers, suggesting targeted screening is beneficial.

Abstract

Annual PSA screening in BRCA2 PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in BRCA1 PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bancroft et al. (2026) studied this question.

synapsesocial.com/papers/699a9ca1482488d673cd2599 https://doi.org/10.1016/j.eururo.2026.01.031

View Full Paper

Ask AI

Bookmark

Implication

Annual PSA screening identifies clinically relevant prostate tumors in BRCA1 and BRCA2 carriers, suggesting targeted screening is beneficial.

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading